Toripalimab-based Neoadjuvant Therapy in LA-HNSCC

NCT05522985 | Active Not Recruiting Phase 2

• 1 other identifier: TJCIHMF&ENT-002
• Study Type: interventional
• Target: 122
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of research is to evaluate the efficacy and safety of Toripalimab combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided into two groups: the test group (Toripalimab combined with AP ) and the control group (AP ); The patients in both groups were treated with three cycles of induction therapy. After the induction therapy, the patients were evaluated and followed up with surgery.

Conditions

Head and Neck Squamous Cell Carcinoma; Neoadjuvant Chemotherapy

Keywords

Head and neck squamous cell carcinoma; Neoadjuvant chemotherapy

Outcome Measures

Primary Outcomes (1)

• PCR

  Pathological complete response

  12 weeks

Secondary Outcomes (1)

• MPR

  12 weeks

Other Outcomes (3)

• ORR

  12 weeks

• OS

  2 years

• PFS

  2 years

Study Arms (2)

Toripalimab combined with AP

EXPERIMENTAL

Nab-Paclitaxel : 260 mg/m2, intravenous infusion, d1, 3-week cycle, 3 cycles; Cisplatin: 75 mg/m2, intravenous infusion, d1, once every 3 weeks, for a total of 3 cycles; Toripalimab : 240 mg, intravenous infusion, d1, once every 3 weeks, for a total of 3 cycles.

Drug: AP combined with or without Toripalimab

AP (Nab-Paclitaxel + Cisplatin)

ACTIVE COMPARATOR

Nab-Paclitaxel: 260 mg/m2, intravenous infusion, d1, 3-week cycle, 3 cycles in total; Cisplatin: 75 mg/m2, intravenous infusion, d1, once every 3 weeks, for a total of 3 cycles;

Drug: AP combined with or without Toripalimab

Interventions

AP combined with or without Toripalimab DRUG

Each participant will receive AP with or without toripalimab, once every 3 weeks for a total of 3 cycles.

AP (Nab-Paclitaxel + Cisplatin); Toripalimab combined with AP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years, male or female;
• Patients with squamous cell carcinoma of head and neck confirmed by histopathology or cytopathology;
• Surgical resection available, clinical stage III or IV without distant metastasis (AJCC 8th)
• Patients who have not received any prior anti-tumor therapy such as chemotherapy, radiotherapy, immunotherapy or biological therapy;
• At least one measurable lesion according to RECIST 1.1 (Appendix 1)
• ECOG performance status 0-1 (Appendix 2);
• Expected survival ≥3 months;
• Function of vital organs meets the following requirements (no blood component, cell growth factor, white blood cell-raising drug, platelet-raising drug, and blood correction drug is allowed within 14 days prior to the first dose of study drug); A.WBC≥3.0x109 /L, ANC≥2.0x109/L B.HB≥90g/L C.Platelets ≥ 100 × 10 9/L D.Serum albumin ≥2.8 g/dL E.Bilirubin total ≤ 1.5 x ULN, ALT ≤ 3.0 x ULN F.Serum creatinine ≤ 1.5xULN or Creatinine clearance \> 60 mL/min G.Activated partial thromboplastin time (APTT) and International normalized ratio (INR) ≤ 1.5 x ULN (screening is allowed for stable doses of Anticoagulant therapy such as low molecular weight heparin or warfarin with INR within the expected therapeutic range of anticoagulants)
• No contraindication to chemotherapy or immunotherapy;
• No history of immune-related disease;
• No uncontrolled pneumonia or lung infection;
• Women of childbearing age must agree to use effective contraceptive measures during the trial; serum or urine pregnancy test must be negative within 72 hours before the first dose of study treatment;
• Good compliance: able to receive the treatment and follow-up, and voluntary to comply with the regulations of the study;
• Patients voluntarily sign the informed consent form.

You may not qualify if:

• Patients with distant metastasis;
• Uncontrolled severe medical diseases, e.g., severe heart disorder (New York Heart Association class II or higher; Appendix 3), cerebrovascular angiopathy, uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc., combined with these medical diseases;
• Previous history of allergy to any component of monoclonal antibody or allergic constitution;
• Uncontrolled cardiac symptoms or diseases, such as NYHA class II or higher Cardiac failure or left ventricular Ejection fraction (LVEF) \<50% as indicated by cardiac echocardiography, Angina unstable, Myocardial infarction within 1 year, patients with clinically significant supraventricular or Ventricular arrhythmia requiring clinical intervention (including QTc interval ≥ 470 ms);
• Serious infection (NCI CTCAE \> Grade 2) occurred within 4 weeks before the first dose of the study drug, such as severe pneumonia, bacteraemia, and infectious complications requiring hospitalisation; Baseline chest imaging suggests active pneumonitis, symptoms and signs of infection within 2 weeks before the first dose of the study drug, or oral or intravenous antibiotic therapy is required for treatment (excluding the use of antibiotics for prophylaxis);
• Unexplained fever \>38.5℃ occurred during the screening period and prior to the first dose (tumor fever judged by the investigator could be enrolled);
• Active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); but not including autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormones; type I diabetes mellitus treated with stable doses of insulin; vitiligo or healed childhood asthma/allergy that does not require any intervention after adulthood;
• History of immunodeficiency, including HIV-positive test, or other acquired, immunodeficiency congenital diseases, or history of organ transplant and allogeneic bone marrow transplant;
• Patients with untreated Chronic hepatitis B or chronic HBV DNA exceeding 500 IU/ml or patients with active Hepatitis C virus (HCV) should be excluded; patients with inactive Hepatitis B surface antigen who have been treated and are stable (HBV DNA\<500IU/ml) and patients with cured Hepatitis C can be enrolled;
• History of interstitial lung disease (excluding Radiation pneumonitis not induced by previous use of hormone therapy) and Noninfectious pneumonitis;
• Patients with active pulmonary tuberculosis infection identified through medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year prior to enrollment, or with a history of active pulmonary tuberculosis infection more than 1 year ago but not receiving regular treatment;
• Patients who have received any of the following treatments:
• A.Use of any investigational product within 4 weeks prior to the first dose of study drug B.Receiving the last dose of antitumor therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within ≤4 weeks prior to the first dose of the study drug C.Patients who require corticosteroids (daily \> 10 mg prednisone equivalent dose) or other immunosuppressants for systemic treatment within 2 weeks prior to the first dose of investigational product, except for the use of corticosteroids for treatment of inflammation localised and prevention of allergic reactions and nausea and vomiting, were excluded. In the absence of active autoimmune disorder, inhaled or topical use of steroids and adrenal corticosteroid replacement with a therapeutic dose \> 10 mg/day of prednisone were allowed.
• D.Having received an antitumor vaccine or any live vaccine within 4 weeks prior to the first dose of the investigational drug E.Major surgery or serious trauma within 4 weeks prior to the first dose of study drug F.Enrollment in another clinical study
• Dementia, mental status changes, or any psychiatric disorder that, in the Investigator's judgment, would interfere with the understanding, giving, or maintenance of informed consent or completion of the questionnaires;

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead

Study Sites (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300000, China

Location

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

toripalimab

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Head and Neck Neoplasms; Neoplasms by Site

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 9, 2022
• First Posted: August 31, 2022
• Study Start: September 2, 2022
• Primary Completion: December 7, 2023
• Study Completion (Estimated): November 7, 2027
• Last Updated: July 17, 2026

Record last verified: 2025-10

Locations

CN (1)